Insights

The European Medicines Agency (EMA) and the European Commission (EC) recently held a multi-stakeholder workshop on the implementation of regulatory sandboxes under the revised EU pharmaceutical legislation.

A regulatory sandbox is a time-limited framework in which developers can test innovative medicines or methodologies in a controlled environment under direct regulatory supervision. It is intended for exceptional cases where a product cannot be developed or authorised under existing requirements because of its scientific or technical characteristics.

The objective is not to lower regulatory standards or create a faster route to marketing authorisation. Instead, the sandbox would allow specific requirements to be adapted when strictly necessary, while maintaining appropriate safeguards for patients, public health and the environment.

For pharmaceutical and biotech companies, this framework could help address regulatory uncertainty earlier, test adapted development approaches and identify a viable path towards authorisation.

However, access is expected to be highly selective. The key elements for implementation are:

• identifying suitable candidates through horizon scanning;
• developing a clear regulatory sandbox plan;
• ensuring transparency and effective communication.

The sandbox plan should define the scientific and regulatory justification, the requirements requiring adaptation, the evidence-generation strategy, risk-mitigation measures and a specific timeline. This will require close coordination across Regulatory Affairs, Clinical Development, CMC, non-clinical and other relevant functions.

Although several operational details remain to be defined, the message is clear: regulatory sandboxes will not be a routine support mechanism or a shortcut to approval. They will be an exceptional, closely supervised instrument for innovations that cannot progress under the current rules.

For developers working at the forefront of pharmaceutical innovation, early regulatory planning, robust scientific justification and cross-functional coordination will be critical.

RPN is available to support pharmaceutical and biotech companies in assessing innovative regulatory opportunities, developing robust scientific and regulatory strategies, and coordinating the cross-functional expertise required to navigate emerging frameworks such as EU regulatory sandboxes.